Claims
- 1. A compound having the formula I:
- 2. The compound of claim 1, wherein said compound is a nucleotide.
- 3. The compound of claim 1, wherein said compound is a nucleotide-tri-phosphate.
- 4. A polynucleotide comprising the compound of claim 1 at one or more positions.
- 5. The polynucleotide of claim 4, wherein said polynucleotide is an enzymatic nucleic acid.
- 6. The enzymatic nucleic acid of claim 5, wherein said nucleic acid is in a hammerhead configuration.
- 7. The enzymatic nucleic acid of claim 6, wherein said nucleic acid is in a hairpin configuration.
- 8. The enzymatic nucleic acid of claim 6, wherein said nucleic acid is in a hepatitis delta virus, group I intron, VS RNA, group II intron or RNase P RNA configuration.
- 9. The compound of claim 1, wherein said compound is xylo riboadenosine.
- 10. The compound of claim 1, wherein said compound is xylo riboguanosine.
- 11. The compound of claim 1, wherein said compound is xylo ribonucleoside phosphoramidite.
- 12. The compound of claim 1, wherein said compound is xylo riboguanosine phosphoramidite.
- 13. The compound of claim 11, wherein said compound is xylo riboadenosine phosphoramidite.
- 14. A mammalian cell comprising the compound of claim 1.
- 15. The mammalian cell of claim 14, wherein said cell is a human cell.
- 16. A mammalian cell comprising the compound of claim 5.
- 17. The mammalian cell of claim 16, wherein said cell is a human cell.
- 18. A method of making a polynucleotide of claim 4.
- 19. A method of modulating gene expression using a polynucleotide of claim 4.
- 20. A pharmaceutical composition comprising a compound of claim 1.
- 21. A pharmaceutical composition comprising a polynucleotide of claim 5.
- 22. The compound of claim 1, wherein said compound is used as an antiviral agent.
- 23. A process for the synthesis of a xylo ribonucleoside phosphoramidite comprising the steps of:
a) oxidation of a 2′ and 5′-protected ribonucleoside using an oxidant followed by reduction using a reducing agent under conditions suitable for the formation of 2′ and 5′-protected xylofuranosyl nucleoside; and b) phosphitylation under conditions suitable for the formation of xylofuranosyl nucleoside phosphoramidite.;
- 24. The process of claim 23, wherein said oxidation is carried out in the presence of chromium oxide, pyridine, and aceticanhydride.
- 25. The process of claim 23, wherein said oxidation is carried out in the presence of dimethylsulfoxide and aceticanhydride.
- 26. The process of claim 23, wherein said oxidation is carried out in the presence of Dess-Martin reagent (periodinane).
- 27. The process of claim 23, wherein said reduction is carried out in the presence of triacetoxy sodium borohydride.
- 28. The process of claim 23, wherein said reduction is carried out in the presence of sodium borohydride
- 29. The process of claim 23, wherein said reduction is carried out in the presence of lithium borohydride,
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of Jasenka Matulic-Adamic, et al., U.S. Provisional Application 60/056,808, entitled “Xylofiranosyl-Containing Nucleoside Phosphoramidites and Polynucleotides”, filed Aug. 22, 1997. This application is hereby incorporated herein by reference in its entirety, including any drawings and figures.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60056808 |
Aug 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09135964 |
Aug 1998 |
US |
Child |
09960192 |
Sep 2001 |
US |